安罗替尼联合PD-1单抗(AK105)治疗13例晚期转移性肝细胞肝癌的疗效及安全性评价  

A preliminary study on effect and safety of anlotinib combined with anti-PD-1 antibody (AK105) in treatment of advanced hepatocellular carcinoma

作　　者：韩春[1] 叶斯斯 李娟[1] 张鹏飞[1] 董苑梅[1] 白莉[1] HAN Chun;YE Sisi;LI Juan;ZHANG Pengfei;DONG Yuanmei;BAI Li(Department of Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心肿瘤内科,北京100853

出　　处：《解放军医学院学报》2020年第9期868-871,共4页Academic Journal of Chinese PLA Medical School

基　　金：国家重点研发计划(2016YFC1303602)。

摘　　要：目的观察安罗替尼联合PD-1单抗(AK105)治疗晚期转移性肝细胞癌的疗效和不良反应。方法选取2019年1-8月在我科使用安罗替尼联合PD-1单抗治疗的13例晚期原发性肝癌患者的临床资料,观察疗效及不良反应。随访时间截至2019年9月27日,结果安罗替尼联合PD-1单抗(AK105)治疗晚期转移性肝癌主要不良反应为手足综合征、皮肤反应及高血压等,未出现3 ~ 4级不良反应。13例患者中,3例达到了部分缓解,6例获得了疾病稳定,客观缓解率为23.1%,疾病控制率为69.2%。结论我们的初步研究显示安罗替尼联合PD-1单抗治疗晚期转移性肝癌不良反应可控,具有较好的疗效。Objective To observe the effect and adverse reactions of anlotinib combined with anti-PD-1 antibody in treatment of advanced hepatocellular carcinoma.Methods Clinical data about 13 patients with advanced hepatocellular carcinoma treated with anlotinib combined with anti-PD-1 antibody from January to August in 2019 in our department were selected,and the curative effect and adverse reactions were observed.The follow-up lasted to September 27th,2019.Results The main adverse reactions of anlotinib combined with anti-PD-1 antibody in the treatment of advanced hepatocellular carcinoma were hand-foot syndrome,skin reaction and hypertension.No grade 3-4 adverse reactions occurred.In the 13 cases,3 cases achieved partial remission,and 6 cases achieved stable disease.The objective effective rate was 23.1%,and the disease control rate was 69.2%.Conclusion Anlotinib combined with anti-PD-1 antibody (AK105) shows good curative effect in the treatment of advanced hepatocellular carcinoma with controllable adverse reactions.

关 键 词：安罗替尼 抗PD-1单抗 肝细胞肝癌 药物不良反应 疾病控制率 

分 类 号：R735.7[医药卫生—肿瘤]